Cost-effectiveness analysis of genotype-guided treatment allocation in patients with alcohol use disorders using naltrexone or acamprosate, using a modeling approach

Ижил төстэй зүйлс

• USE OF NALTREXONE IN THE TREATMENT OF ALCOHOL USE DISORDERS IN PATIENTS WITH CONCOMITANT MAJOR MENTAL ILLNESS
  -н: MAXWELL, S.
  Хэвлэсэн: (2001)
• PHARMACOLOGICAL MECHANISMS OF NALTREXONE AND ACAMPROSATE IN THE PREVENTION OF RELAPSE IN ALCOHOL DEPENDENCE
  -н: LITTLETON, J.
  Хэвлэсэн: (2005)
• Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful?
  -н: Maisel, N.C
  Хэвлэсэн: (2013)
• Cost-effectiveness of extended release naltrexone to prevent relapse among criminal justice-involved individuals with a history of opioid use disorder
  -н: Murphy, S.M
  Хэвлэсэн: (2017)
• Using a 'wellbeing' cost-effectiveness approach to improve resource allocation in social care
  -н: Forder, J.
  Хэвлэсэн: (2015)